Special Issue "Preclinical and Clinical Advances in Ovarian Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2020).
Interests: pathobiology of gynecologic diseases; ovarian cancer; ovarian cancer biology and preclinical therapy; drug repurposing
Special Issues and Collections in MDPI journals
Ovarian cancer is a major public health concern and remains the deadliest form of gynecological malignancy. Despite survival rates for a number of solid tumors having improved significantly in the last 50 years, the five-year overall survival rate for ovarian cancer has remained stagnant at around 45–47% since the introduction of platinum–taxane chemotherapy following debulking surgery. Whilst in many areas, ovarian cancer continues to elude our understanding, the recent pace of discovery presages a welcome change in overall survival for individuals who will suffer from this disease in the near future.
This Special Issue anticipates an expansion in preclinical and clinical advances in the field. Topics include advances in epidemiology, risk factors, early symptomatology, diagnosis and staging, disease prognosis, prevention, early screening methods, pathobiology of disease initiation and dissemination, biomarkers of disease progression and recurrence, histopathological heterogeneity, genetic expression profiling and molecular subtypes, new surgical strategies, adjuvant therapies, relapse and treatment resistance, and targeted therapies. In particular, this Special Issue will highlight new preclinical models of disease progression, new cell lines and animal models representing the disease, new drugs that show promise for treating ovarian cancer in preclinical studies, and new clinical trials and strategies that contribute to a better quality of life for ovarian cancer patients.
Prof. Carlos M. Telleria
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- ovarian cancer
- new drugs
- clinical trials
- targeted therapy
- pathobiology of the disease